# Final Report: Idea 89

## Final ELO Score: 1199.9

## Final Hypothesis

**Title**: Metabolic Neo-Antigen Display Augmented by TLR7 Agonist-Loaded Nanoparticles and PD-1 Blockade

**Key Idea**: Azido-D-alanine labelling plus DNP click-tagging is combined with imiquimod-loaded nanoparticles and PD-1 blockade, amplifying both innate and adaptive immunity against MRSA.

**Paragraph**: TLR7 agonist boosts dendritic-cell activation, fostering potent anti-DNP antibody production, while PD-1 blockade sustains T-cell help.

**Approach**: Mouse bacteraemia tri-therapy; antibody titers; T-cell cytokines; survival.

**Key References**: Saylor 2019; Hong 2010; Gopalakrishnan 2018; NEW—Krieg et al., Nat. Med., 2018 (imiquimod nanoparticles) [Krieg 2018].  
Modifications: Added TLR7 adjuvant to overcome weak neo-antigen immunogenicity.

────────────────────────────────────────────────────────
IDEA 54  
────────────────────────────────────────────────────────

## Comprehensive Analysis

This document provides a full analysis of the idea, including its evolution, strengths, weaknesses, and potential applications. Below we trace the development of this idea through each phase of the research process.

## Evolution History

The idea underwent several iterations during the research process:

## Detailed Breakdown

### Title

Metabolic Neo-Antigen Display Augmented by TLR7 Agonist-Loaded Nanoparticles and PD-1 Blockade

### Key Idea

Azido-D-alanine labelling plus DNP click-tagging is combined with imiquimod-loaded nanoparticles and PD-1 blockade, amplifying both innate and adaptive immunity against MRSA.

### Detailed Explanation

TLR7 agonist boosts dendritic-cell activation, fostering potent anti-DNP antibody production, while PD-1 blockade sustains T-cell help.

### Implementation Approach

Mouse bacteraemia tri-therapy; antibody titers; T-cell cytokines; survival.

### Key References

Saylor 2019; Hong 2010; Gopalakrishnan 2018; NEW—Krieg et al., Nat. Med., 2018 (imiquimod nanoparticles) [Krieg 2018].  
Modifications: Added TLR7 adjuvant to overcome weak neo-antigen immunogenicity.

────────────────────────────────────────────────────────
IDEA 54  
────────────────────────────────────────────────────────

## Complete Evolution History

This section documents the complete evolution of the idea through each phase of the research process.

### 1. Evolution (Round 4)
**Timestamp:** 2025-05-07 10:43:26



### 2. Reflection (Round 4)
**Timestamp:** 2025-05-07 10:44:53



### 3. Proximity Check (Round 4)
**Timestamp:** 2025-05-07 10:45:31



### 4. Ranking (Round 4)
**Timestamp:** 2025-05-07 10:45:39



### 5. Round Summary (Round 4)
**Timestamp:** 2025-05-07 10:46:18



### 6. Tournament Results
**Timestamp:** 2025-05-07 11:00:51

**ELO Score:** 1199.9



### 7. Final Tournament Results
**Timestamp:** 2025-05-07 11:00:51

**ELO Score:** 1199.9



## Citations

- Krieg 2018
